Curosurf

Curosurf

Manufacturer:

Chiesi

Distributor:

Pacific Healthcare
Concise Prescribing Info
Contents
Poractant alfa: Natural surfactant from the alveolar surface of porcine lungs containing phospholipids (phosphatidylcholine approx 70% of total phospholipid content) & surfactant specific hydrophobic low-molecular wt proteins SP-B & SP-C 1-2%
Indications/Uses
Treatment of resp distress syndrome (RDS) in pre-term babies. Prophylactic use in premature infants at risk for RDS.
Dosage/Direction for Use
Rescue treatment 100-200 mg/kg body wt (1.25-2.5 mL/kg) via endotracheal tube, may be administered w/ additional doses of 100 mg/kg at 12 hrly intervals for infants still requiring assisted ventilation & supplementary oxygen. Prophylaxis Administer 100-200 mg/kg w/in 15 min after birth. Further doses of 100 mg/kg can be given 6-12 hr after the 1st dose then at 12 hrly intervals, if necessary. Max total dose: 300-400 mg/kg.
Special Precautions
Correction of acidosis, hypotension, anaemia, hypoglycaemia & hypothermia. Preterm infants.
Adverse Reactions
Pulmonary haemorrhage.
MIMS Class
Other Drugs Acting on the Respiratory System
ATC Classification
R07AA02 - natural phospholipids ; Belongs to the class of lung surfactants. Used in the treatment of respiratory diseases.
Presentation/Packing
Form
Curosurf intratracheal susp 80 mg/mL
Packing/Price
(vial) 1.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in